JonesTrading analyst Catherine Novack has maintained their bullish stance on WVE stock, giving a Buy rating on August 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Catherine Novack’s rating is based on several promising aspects of Wave Life Sciences’ recent data release. Despite the 200mg multi-dose results being somewhat underwhelming, they still demonstrated the company’s ability to edit liver RNA in AATD patients, which is a positive indicator of their technology’s potential. Additionally, the acute phase response in one patient showed significantly higher serum AAT levels, suggesting that there is room for improvement with increased dosing.
Moreover, the safety profile of WVE-006 was favorable, and the company plans to explore higher doses, with 400mg multi-dose data expected in the first quarter of 2026. Although the dose response between 200mg and 400mg was modest, the potential for higher efficacy with increased dosing remains. Compared to competitors like Beam, Wave’s RNA editor showed similar total AAT levels, and the potential for monthly dosing could enhance its therapeutic viability. These factors collectively contribute to Novack’s Buy rating for Wave Life Sciences.
In another report released on August 20, Canaccord Genuity also maintained a Buy rating on the stock with a $19.00 price target.